Common use of The Parties’ Exclusivity Covenants During the Option Period for Collaboration Targets Clause in Contracts

The Parties’ Exclusivity Covenants During the Option Period for Collaboration Targets. Each Party agrees that, except in the performance of its obligations or exercise of its rights under this Agreement and except as set forth in Section 2.1.2, Section 2.2, Section 10.4.3 or Section 10.4.4, neither it nor any of its Affiliates will work independently or for or with any Third Party (including the grant of any license to any Third Party) with respect to discovery, research, development, manufacture or commercialization in the Field of an oligonucleotide that is designed to bind to the RNA that encodes a Collaboration Target from the date such gene target was designated a Collaboration Target under this Agreement through the expiration or earlier termination of the applicable Option Period.

The Parties’ Exclusivity Covenants During the Option Period for Collaboration Targets. Each Party agrees that, except in the performance of its obligations or exercise of its rights under this Agreement and except as set forth in Section 2.1.2, Section 2.22.1.3, Section 10.4.3 10.6.3 or Section 10.4.410.6.4, neither it nor any of its Affiliates will work independently or for or with any Third Party (including the grant of any license to any Third Party) with respect to discovery, research, development, manufacture or commercialization in the Field of an oligonucleotide Oligonucleotide that is designed to bind to the RNA that encodes a Collaboration Target from the date such gene target was designated a Collaboration Target under this Agreement through the expiration or earlier termination of the applicable Option PeriodPeriods for all Collaboration Programs directed to such Collaboration Target.

The Parties’ Exclusivity Covenants During the Option Period for Collaboration Targets. Each On a Collaboration Target-by-Collaboration Target basis, each Party agrees that, except in the performance of its obligations or exercise of its rights under this Agreement and except as set forth in Section 2.1.2, Section 2.22.1.3, Section 10.4.3 10.4.2 or Section 10.4.410.4.3, neither it nor any of its Affiliates will not work independently or for or with any of its Affiliates or any Third Party (including the grant of any license to any Third Party) with respect to discovery, research, development, manufacture or commercialization in the Field of an oligonucleotide ASO that is designed to bind to the RNA that encodes a such Collaboration Target in the Field from the date such gene target was designated a Collaboration Target under this Agreement Effective Date through the expiration or earlier termination of the applicable Option Period.

The Parties’ Exclusivity Covenants During the Option Period for Collaboration Targets. Each Party agrees that, except in the performance of its obligations or exercise of its rights under this Agreement and except as set forth in Section 2.1.2, Section 2.2, Section 10.4.3 or Section 10.4.4, neither it nor any of its Affiliates will work independently or for or with any Third Party (including the grant of any license to any Third Party) with respect to discovery, research, development, manufacture or commercialization in the Field of an oligonucleotide Oligonucleotide that is designed to bind to the RNA that encodes a Collaboration Target from the date such gene target was designated a Collaboration Target under this Agreement through the expiration or earlier termination of the applicable Option Period.. (e)

The Parties’ Exclusivity Covenants During the Option Period for Collaboration Targets. Each On a Collaboration Target-by-Collaboration Target basis, each Party agrees that, except in the performance of its obligations or exercise of its rights under this Agreement and except as set forth in Section 2.1.2, Section 2.22.1.3, Section 10.4.3 10.4.2 or Section 10.4.410.4.3, neither it nor any of its Affiliates will not work independently or for or with any of its Affiliates or any Third Party (including the grant of any license to any Third Party) with respect to discovery, research, development, manufacture or commercialization in the Field of an oligonucleotide ASO that is designed to bind to the RNA that encodes a such Collaboration Target in the Field from the date such gene target was designated a Collaboration Target under this Agreement through the earlier of (i) the License Effective Date with respect to the Collaboration Program for such Collaboration Target and (ii) the expiration or earlier termination of the applicable Option Period.